168 related articles for article (PubMed ID: 32706496)
1. Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma.
Igata M; Yagi Y; Hanatani S; Sakaguchi M; Ishii N; Yoshinaga K; Kawashima J; Motoshima H; Araki E
J Diabetes Investig; 2021 Apr; 12(4):668-671. PubMed ID: 32706496
[TBL] [Abstract][Full Text] [Related]
2. Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes.
Oshige T; Nakamura Y; Sasaki Y; Kawano S; Ohki T; Tsuruta M; Tokubuchi I; Nakayama H; Yamada K; Ashida K; Tajiri Y; Nomura M
Intern Med; 2019 Nov; 58(21):3125-3128. PubMed ID: 31243214
[TBL] [Abstract][Full Text] [Related]
3. A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
Lamos EM; Levitt DL; Munir KM
Prim Care Diabetes; 2016 Feb; 10(1):60-5. PubMed ID: 26670921
[TBL] [Abstract][Full Text] [Related]
4. Bromocriptine treatment of prolactinoma restores growth hormone secretion and causes catch-up growth in a prepubertal child.
Sakazume S; Obata K; Takahashi E; Yoshino A; Murakami N; Sakuta R; Murai T; Nagai T
Eur J Pediatr; 2004 Aug; 163(8):472-4. PubMed ID: 15160292
[TBL] [Abstract][Full Text] [Related]
5. Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.
Schwartz SS; Zangeneh F
Postgrad Med; 2016 Nov; 128(8):828-838. PubMed ID: 27458683
[TBL] [Abstract][Full Text] [Related]
6. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
Chamarthi B; Cincotta AH
Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
8. Bromocriptine: its place in type 2 diabetes Tx.
Sando KR; Taylor J
J Fam Pract; 2011 Nov; 60(11):E1-5. PubMed ID: 22049355
[TBL] [Abstract][Full Text] [Related]
9. Resolution of migraine following bromocriptine treatment of a prolactinoma (pituitary microadenoma).
Hartman N; Voron SC; Hershman JM
Headache; 1995; 35(7):430-1. PubMed ID: 7672963
[TBL] [Abstract][Full Text] [Related]
10. Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study.
Roe ED; Chamarthi B; Raskin P
J Diabetes Res; 2015; 2015():834903. PubMed ID: 26060825
[TBL] [Abstract][Full Text] [Related]
11. Normal growth and pubertal development during bromocriptine therapy in two patients with prolactinoma.
Kamel N; Uysal AR; Cesur V; Erdoğan G; Başkal N
Endocr J; 1995 Aug; 42(4):581-6. PubMed ID: 8556068
[TBL] [Abstract][Full Text] [Related]
12. Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes.
Scranton R; Cincotta A
Expert Opin Pharmacother; 2010 Feb; 11(2):269-79. PubMed ID: 20030567
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Bromocriptine-QR as an Adjunctive Therapy on Glycemic Control in Subjects with Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
Yanto TA; Budiputri CL; Muljono MP; Chandra S
J ASEAN Fed Endocr Soc; 2024; 39(1):95-105. PubMed ID: 38863918
[TBL] [Abstract][Full Text] [Related]
14. Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.
Chamarthi B; Gaziano JM; Blonde L; Vinik A; Scranton RE; Ezrokhi M; Rutty D; Cincotta AH
J Diabetes Res; 2015; 2015():157698. PubMed ID: 26060823
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus.
Kabir MT; Ferdous Mitu J; Akter R; Akhtar MF; Saleem A; Al-Harrasi A; Bhatia S; Rahman MS; Damiri F; Berrada M; Rahman MH
Environ Sci Pollut Res Int; 2022 Jul; 29(31):46385-46404. PubMed ID: 35486279
[TBL] [Abstract][Full Text] [Related]
16. Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus.
Kerr JL; Timpe EM; Petkewicz KA
Ann Pharmacother; 2010 Nov; 44(11):1777-85. PubMed ID: 20978217
[TBL] [Abstract][Full Text] [Related]
17. Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment.
Zacharieva S; Stoeva I; Andreeva M; Kalinov K; Matrozov P; Andonova K
Methods Find Exp Clin Pharmacol; 1996 Nov; 18(9):593-7. PubMed ID: 9010834
[TBL] [Abstract][Full Text] [Related]
18. PGAM5-CypD pathway is involved in bromocriptine-induced RIP3/MLKL-dependent necroptosis of prolactinoma cells.
Zhang SL; Tang HB; Hu JT; Zang ZL; Ding X; Li S; Yang H
Biomed Pharmacother; 2019 Mar; 111():638-648. PubMed ID: 30611988
[TBL] [Abstract][Full Text] [Related]
19. Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine.
Orrego JJ; Chandler WF; Barkan AL
Pituitary; 2000 Nov; 3(3):189-92. PubMed ID: 11383485
[TBL] [Abstract][Full Text] [Related]
20. [Bromocriptine monotherapy of a prolactinoma causing erectile dysfunction].
López Cubillana P; Hita Rosino E; Asensio Egea L; Rigabert Montiel M; Hita Villaplana G; Server Pastor G; Server Falgás G
Arch Esp Urol; 1997 Jun; 50(5):526-8. PubMed ID: 9382597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
